SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing significant volatility and trending status driven by intense speculation around a potential short squeeze, with community members highlighting an increasing cost-to-borrow rate and low share availability. Investors are closely monitoring the upcoming earnings report, viewing it as a critical catalyst while debating the company's valuation and the effectiveness of its growth strategy compared to broader AI sector trends.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is experiencing intense volatility as the community speculates on technical breakouts and potential short-squeeze activity fueled by social media buzz. Investors remain divided, with some betting on a rapid move upward based on technical patterns, while others express frustration over the stock's persistent sideways movement and lack of major corporate news.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is currently trending following the announcement of a massive $2.8 billion AI infrastructure expansion with Yotta Data Services, which has reignited intense community debate regarding the company's valuation, contract execution risk, and short-interest dynamics. While bullish investors point to the significant project pipeline and strategic partnerships as signs of a pending breakout, bears continue to express skepticism regarding the company's revenue recognition, lack of formal guidance, and history of unfulfilled promises.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is currently trending as investors weigh the company's recent earnings beat and strategic capital moves against ongoing concerns regarding high cash burn and dilution risk. Community discussion is heavily focused on the company's long-term potential tied to the R2 platform ramp-up and production milestones, with investors debating whether current price levels present a buying opportunity or a signal of deeper volatility.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors digest news of potential FDA leadership changes, with the community closely tracking rumors of a former company VP being considered for a key regulatory role. The optimism is fueled by strong HOPE-3 Phase 3 clinical data for its lead therapy, leading many to believe that the path to approval is nearing completion despite recent price volatility caused by speculative short-selling.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is trending as traders speculate on potential price appreciation, driven by a recent licensing agreement and anticipation of clinical data presentations. While some community members are focused on a possible short squeeze and technical breakouts, others remain cautious, citing risks associated with the company's capital structure and previous stock performance.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox shares are under significant downward pressure following a guidance cut that cited user growth friction caused by new age-verification and safety measures. While some community members view the dip as an oversold buying opportunity, others are heavily focused on the company's lack of profitability and the broader debate surrounding platform safety.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is seeing heavy retail interest and positive price momentum as investors speculate on the potential for its proprietary electro-optic polymer technology to become a critical component in next-generation AI and high-speed data center infrastructure. The community is actively debating the company's path toward commercialization and watching for potential institutional partnerships or licensing deals that could validate its long-term growth potential.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing intense momentum as the community monitors its aggressive expansion plans, including a significant footprint increase in Houston to meet massive demand for 800G and 1.6T transceivers. While bullish investors view this scaling as proof of institutional demand and a clear supply chain advantage, bears are highlighting concerns regarding the company's valuation, history of losses, and potential insider selling.

AIOS Tech, Inc. is an investment holding company, which engages in the provision of financing solutions to small- and mid-size enterprises. The company was founded on May 29, 2012 and is headquartered in Shanghai, China.

AIOS Tech Inc. - Ordinary Shares - Class A

AIOS Tech Inc.

AIOS Tech Inc. is generating intense community interest driven by micro-float momentum and speculative trading dynamics often seen in low-float, high-volatility setups. Traders are actively debating the sustainability of the stock's recent price action, with some highlighting potential for short squeezes while others warn of risks related to debt and dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Editas Medicine (NASDAQ:EDIT) Stock Passes Above Fifty Day Moving Average - Here's Why

Editas Medicine (NASDAQ:EDIT) Shares Pass Above Fifty Day Moving Average - Time to Sell...

Editas Medicine (NASDAQ:EDIT) Share Price Passes Above 50 Day Moving Average - Here's What Happened

Editas Medicine (NASDAQ:EDIT) Stock Passes Above Fifty Day Moving Average - Should You Sell...

Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report?

Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) have received an average rating of "Moderate Buy" from the eight brokerages that are covering the firm, MarketBeat reports. One analyst...

Editas Medicine (NASDAQ:EDIT) Downgraded by Wall Street Zen to Sell

Wall Street Zen cut Editas Medicine from a "hold" rating to a "sell" rating in a report on Saturday...

Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Research Weighs in on Editas Medicine FY2028 Earnings

Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Analysts at Zacks Research issued their FY2028 earnings estimates for Editas Medicine in a note issued to investors on Monday, March 23rd. Zacks...

Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have...

Is Editas Medicine Going to $0?

Key PointsEditas Medicine has been on fire over the trailing-12-month period...

Editas Medicine Details In Vivo CRISPR Plan, Targets Year-End Human Proof-of-Concept for EDIT-401

Editas Medicine (NASDAQ:EDIT) executives outlined the company's in vivo CRISPR gene-editing strategy and near-term clinical plans during a recent discussion featuring President and CEO Gilmore...

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

EDIT
Editas Medicine Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest EDIT News

EDITEditas Medicine Inc